Estonian biotechnology company Icosagen Cell Factory (ICF) OÜ starts with preparations for developing and engineering a novel toolbox for enhanced cell line, made possible by funding from European Commission’s Horizon 2020 SME Instrument

← Back to press releases

Consultants from Invent Baltics helped ICF to compile the successful SME Instrument 1st phase proposal „IcoCell“ to the European Commission’s Horizon 2020 programme. During the 1st phase of the project will compile a detailed business plan and a feasibility study including market research, a freedom-to-operate analysis, technological feasibility study and a commercialization strategy

ICF is an Estonian biotechnology company developing novel technologies and providing research services to the biopharmaceutical and biotechnology industries and to academia. A portfolio of proprietary technologies (e.g. QMCF Technology for protein production) and custom-tailored services for protein, antibody, VLP. etc., production are offered.

The SME Instrument is a funding instrument under the Horizon 2020 Research and Innovation program that supports innovative Small and Medium-sized Enterprises in Europe and associated countries. The instrument aims to fill the gaps in funding for research and innovation at early stages and thereby accelerate the exploitation of novel solutions to address key societal challenges or enabling technologies. The SME Instrument Phase 1 funding supports SMEs to cover the funding for initial feasibility assessment and business modelling for the novelty. Phase 2 funding is targeted to SMEs with particular focus on product development, demonstration activities and market replication. In 2015 and onwards, there will be a cut-off at the end of each quarter. The next cut-off date for Phase 1 and Phase 2 project proposals is March 18 and June 17, 2015. Invent Baltics OÜ provides initial consultancy regarding funding opportunities within the Horizon 2020 Research and Innovation program free of charge.

More information
Silver Toomla
+372 51 71 781

← Back to press releases